Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$1.65
+5.1%
$1.41
$1.11
$5.00
$439.13M1.771.50 million shs1.45 million shs
Genelux Co. stock logo
GNLX
Genelux
$2.45
-3.5%
$2.67
$1.60
$5.89
$92.45M-0.33193,116 shs127,667 shs
Kamada Ltd. stock logo
KMDA
Kamada
$6.89
-0.9%
$6.58
$4.74
$9.16
$396.04M0.9490,830 shs52,890 shs
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$4.24
-1.2%
$4.56
$2.86
$9.31
$377.97M1.821.87 million shs2.75 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
+1.95%+2.61%+18.05%-13.74%-59.95%
Genelux Co. stock logo
GNLX
Genelux
-1.55%-7.64%-11.81%-44.30%-3.05%
Kamada Ltd. stock logo
KMDA
Kamada
+4.83%+1.16%+3.89%-2.11%+31.13%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-1.61%-6.94%-25.52%-32.01%-18.75%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
3.4084 of 5 stars
3.54.00.00.03.33.30.6
Genelux Co. stock logo
GNLX
Genelux
1.6557 of 5 stars
3.62.00.00.03.30.00.0
Kamada Ltd. stock logo
KMDA
Kamada
3.85 of 5 stars
3.43.00.00.03.41.73.1
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
3.2611 of 5 stars
4.51.00.00.02.73.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
3.00
Buy$9.32464.85% Upside
Genelux Co. stock logo
GNLX
Genelux
3.20
Buy$17.75624.49% Upside
Kamada Ltd. stock logo
KMDA
Kamada
2.75
Moderate Buy$14.67112.87% Upside
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
3.00
Buy$25.75507.31% Upside

Current Analyst Ratings Breakdown

Latest GNLX, AUTL, KMDA, and VERV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Kamada Ltd. stock logo
KMDA
Kamada
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/8/2025
Genelux Co. stock logo
GNLX
Genelux
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.00
5/8/2025
Kamada Ltd. stock logo
KMDA
Kamada
Sidoti
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/15/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$18.00 ➝ $24.00
4/15/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight
4/15/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $39.00
4/14/2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $25.00
4/10/2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/1/2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
3/31/2025
Genelux Co. stock logo
GNLX
Genelux
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
3/25/2025
Genelux Co. stock logo
GNLX
Genelux
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
$9.01M48.73N/AN/A$0.64 per share2.58
Genelux Co. stock logo
GNLX
Genelux
$8K11,556.34N/AN/A$0.73 per share3.36
Kamada Ltd. stock logo
KMDA
Kamada
$167.24M2.37$0.38 per share17.90$4.25 per share1.62
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
$59.61M6.34N/AN/A$7.31 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)
Genelux Co. stock logo
GNLX
Genelux
-$28.30M-$0.88N/AN/AN/AN/A-105.05%-80.16%8/13/2025 (Estimated)
Kamada Ltd. stock logo
KMDA
Kamada
$8.28M$0.2924.6121.530.979.92%6.30%4.49%8/13/2025 (Estimated)
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$200.07M-$2.11N/AN/AN/A-807.65%-35.23%-27.65%8/14/2025 (Estimated)

Latest GNLX, AUTL, KMDA, and VERV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Kamada Ltd. stock logo
KMDA
Kamada
$0.07$0.07N/A$0.07$154.06 million$44.02 million
5/14/2025Q1 2025
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
-$0.71-$0.35+$0.36-$0.35$7.13 million$32.98 million
5/8/2025Q1 2025
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million
5/8/2025Q1 2025
Genelux Co. stock logo
GNLX
Genelux
-$0.24-$0.21+$0.03-$0.21N/AN/A
3/28/2025Q4 2024
Genelux Co. stock logo
GNLX
Genelux
-$0.17-$0.26-$0.09-$0.26N/AN/A
3/20/2025Q4 2024
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/AN/AN/AN/AN/A
Genelux Co. stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
Kamada Ltd. stock logo
KMDA
Kamada
N/AN/AN/AN/AN/A
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/AN/AN/AN/AN/A

Latest GNLX, AUTL, KMDA, and VERV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/5/2025
Kamada Ltd. stock logo
KMDA
Kamada
--$0.203/17/20253/17/20254/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
N/A
13.69
13.69
Genelux Co. stock logo
GNLX
Genelux
N/A
6.47
6.47
Kamada Ltd. stock logo
KMDA
Kamada
N/A
4.84
2.73
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
N/A
13.05
13.05

Institutional Ownership

CompanyInstitutional Ownership
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
72.83%
Genelux Co. stock logo
GNLX
Genelux
37.33%
Kamada Ltd. stock logo
KMDA
Kamada
20.38%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
97.11%

Insider Ownership

CompanyInsider Ownership
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
25.70%
Genelux Co. stock logo
GNLX
Genelux
9.30%
Kamada Ltd. stock logo
KMDA
Kamada
36.10%
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
19.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Autolus Therapeutics plc stock logo
AUTL
Autolus Therapeutics
330266.14 million197.71 millionOptionable
Genelux Co. stock logo
GNLX
Genelux
1037.74 million31.33 millionNot Optionable
Kamada Ltd. stock logo
KMDA
Kamada
36057.48 million36.73 millionOptionable
Verve Therapeutics, Inc. stock logo
VERV
Verve Therapeutics
11089.14 million68.32 millionOptionable

Recent News About These Companies

FY2025 EPS Estimate for Verve Therapeutics Lifted by Analyst
Research Analysts Offer Predictions for VERV FY2026 Earnings
Cantor Fitzgerald Analysts Raise Earnings Estimates for VERV
Q3 EPS Forecast for Verve Therapeutics Raised by Analyst

New MarketBeat Followers Over Time

Media Sentiment Over Time

Autolus Therapeutics stock logo

Autolus Therapeutics NASDAQ:AUTL

$1.65 +0.08 (+5.10%)
Closing price 04:00 PM Eastern
Extended Trading
$1.64 -0.01 (-0.61%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Genelux stock logo

Genelux NASDAQ:GNLX

$2.45 -0.09 (-3.54%)
Closing price 04:00 PM Eastern
Extended Trading
$2.51 +0.06 (+2.45%)
As of 05:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Kamada stock logo

Kamada NASDAQ:KMDA

$6.89 -0.06 (-0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$6.87 -0.02 (-0.29%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Verve Therapeutics stock logo

Verve Therapeutics NASDAQ:VERV

$4.24 -0.05 (-1.17%)
Closing price 04:00 PM Eastern
Extended Trading
$4.19 -0.05 (-1.18%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.